Department of Emerging and Re-emerging Infectious Diseases
Conducting research focused on predicting and detecting epidemics; understanding pathogenicity, infectivity, and transmission routes; and developing treatment and prevention methods
Detecting transmission of pathogens
through a genomic analysis
Translational research on emerging and re-emerging
infectious diseases on a global scale(Kido)
Development of vaccines and therapeutic drugs
“Helibodies” (Helix + Antibody = Helibody)
Our research group has generated a molecular-targeting peptide with a stable helix-loop-helix structure called "Helibody" (molecular weight: 4K) as a new drug modality with antibody-like activity. We have succeeded in obtaining helibodies that bind extremely strongly to various disease-related proteins. Therefore, we screened our original helibody libraries against various virus surface proteins to obtain the helibodies that inhibit the infections.
Molecular-targeting peptide “Helibody” for the inhibition and diagnosis of viral infections
Molecular-targeting peptide “Helibody” for the inhibition and diagnosis of viral infections(Fujii)